Baidu
map

警惕!这类药门诊被禁用!六大科室纳入重点监控!

2017-07-06 淅水 三甲传真

当下中国,抗菌药物使用正面临着前所未有的挑战。山东省卫计委近日发布了《关于加强抗菌药物临床应用管理遏制细菌耐药工作的通知》,对各级医疗机构的采购、管理和使用做出了详细的规定。

当下中国,抗菌药物使用正面临着前所未有的挑战。山东省卫计委近日发布了《关于加强抗菌药物临床应用管理遏制细菌耐药工作的通知》,对各级医疗机构的采购、管理和使用做出了详细的规定。

■所有医院门诊禁用特殊使用级抗菌药物

通知要求严格控制特殊使用级抗菌药物使用,门诊不得使用特殊使用级抗菌药物。同时对住院患者使用级抗菌药物治疗做出硬性规定:

第一:接受特殊使用级抗菌药物治疗的住院患者使用抗菌药物前微生物送检率不得低于百分之八十。

第二:临床应用特殊使用级抗菌药物应当严格掌握用药指证,经具有抗菌药物临床应用经验的感染或相关专业专家会诊,由具有高级专业技术职务任职资格的医师开具处方或医嘱后方可使用。

第三:因抢救生命垂危的患者等紧急情况,未经会诊同意或确需越级使用抗菌药物的,处方量不得超过一日用量,并详细记录用药指证,于二十四小时内补办越级使用抗菌药物的必要手续。

■六大科室重点监管,并纳入绩效考核

通知明确提出了,要对各医院的重症监护病房、新生儿室、血液科病房、呼吸科病房、神经科病房、烧伤病房等科室和基层医疗机构,重点加强抗菌药物管理,定期组织相关专家对抗菌药物处方、医嘱进行重点专项抽查点评,并将点评结果作为科室和医务人员处方权授予及绩效考核的重要依据。

其实关于这一点,已经有越来越多的医院把合理用药纳入医生的绩效考核。三甲传真在昨天发布的文章《大工作!医生多开药被公示》一文中就提到:辽宁卫计委也将要把合理用药作为科室和医师绩效分配、考核奖惩、限制或取消处方权的主要依据,对出现超常处方三次以上且无正当理由的医师提出警告,限制其处方权;限制处方权后,仍连续二次以上出现超常处方且无正当理由的,取消其处方权。

而山东卫计委此次也做出同样的要求:对出现抗菌药物超常处方三次以上且无正当理由的医师提出警告,限制其特殊使用级和限制使用级抗菌药物处方权;限制处方权后,仍出现超常处方且无正当理由的,取消其抗菌药物处方权,且六个月内不得恢复。

■所有村卫生室、诊所输液要上报审核

通知要求:村卫生室、诊所和社区卫生服务站使用抗菌药物开展静脉输注活动,要经县级卫生计生行政部门核准。

这一点尤其要引起所有基层医生的高度重视。抗菌药物的使用今后要上报审核不仅是大势所趋,更要严守操作规程。因为这不仅是为患者负责,更是为自己负责!前不久曾有媒体报道,天津一诊所医生违反操作规程,对患者抗菌药物进行静脉滴注,导致其出现过敏反应,经抢救无效后死亡。法院审理此案后,以医疗事故罪判处该医生有期徒刑一年六个月。

从全国情况看,今后对基层医疗机构的抗菌药物临床应用管理,只会越来越严格,越来越规范。

■为各级各类医院明确具体品规数量

通知对三级综合医院、儿童医院、妇产医院、二级综合医院、口腔医院、肿瘤医院、精神病医院等各级各类医疗机构抗菌药物品种数量做出了明确规定。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1949077, encodeId=598019490e713, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Apr 24 22:45:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219469, encodeId=011d219469d3, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:31:53 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219370, encodeId=c03b2193e0c1, content=支持一下,需要大家努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Jul 07 07:01:34 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219243, encodeId=abcd2192439a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Jul 06 20:07:03 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219219, encodeId=77ee21921960, content=确实应该严格限制抗生素的应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Thu Jul 06 18:49:33 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219214, encodeId=6fe8219214a2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:04:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219203, encodeId=4f2e2192032a, content=严格用药指征,严格限制抗生素使用,。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jul 06 16:02:09 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1949077, encodeId=598019490e713, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Apr 24 22:45:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219469, encodeId=011d219469d3, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:31:53 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219370, encodeId=c03b2193e0c1, content=支持一下,需要大家努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Jul 07 07:01:34 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219243, encodeId=abcd2192439a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Jul 06 20:07:03 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219219, encodeId=77ee21921960, content=确实应该严格限制抗生素的应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Thu Jul 06 18:49:33 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219214, encodeId=6fe8219214a2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:04:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219203, encodeId=4f2e2192032a, content=严格用药指征,严格限制抗生素使用,。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jul 06 16:02:09 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-07 Chongyang Zhang

    签到学习了很多。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1949077, encodeId=598019490e713, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Apr 24 22:45:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219469, encodeId=011d219469d3, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:31:53 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219370, encodeId=c03b2193e0c1, content=支持一下,需要大家努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Jul 07 07:01:34 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219243, encodeId=abcd2192439a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Jul 06 20:07:03 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219219, encodeId=77ee21921960, content=确实应该严格限制抗生素的应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Thu Jul 06 18:49:33 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219214, encodeId=6fe8219214a2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:04:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219203, encodeId=4f2e2192032a, content=严格用药指征,严格限制抗生素使用,。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jul 06 16:02:09 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-07 清风拂面

    支持一下,需要大家努力

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1949077, encodeId=598019490e713, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Apr 24 22:45:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219469, encodeId=011d219469d3, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:31:53 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219370, encodeId=c03b2193e0c1, content=支持一下,需要大家努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Jul 07 07:01:34 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219243, encodeId=abcd2192439a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Jul 06 20:07:03 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219219, encodeId=77ee21921960, content=确实应该严格限制抗生素的应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Thu Jul 06 18:49:33 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219214, encodeId=6fe8219214a2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:04:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219203, encodeId=4f2e2192032a, content=严格用药指征,严格限制抗生素使用,。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jul 06 16:02:09 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 三生有幸9135

    学习一下谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1949077, encodeId=598019490e713, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Apr 24 22:45:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219469, encodeId=011d219469d3, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:31:53 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219370, encodeId=c03b2193e0c1, content=支持一下,需要大家努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Jul 07 07:01:34 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219243, encodeId=abcd2192439a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Jul 06 20:07:03 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219219, encodeId=77ee21921960, content=确实应该严格限制抗生素的应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Thu Jul 06 18:49:33 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219214, encodeId=6fe8219214a2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:04:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219203, encodeId=4f2e2192032a, content=严格用药指征,严格限制抗生素使用,。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jul 06 16:02:09 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 QFXL123456

    确实应该严格限制抗生素的应用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1949077, encodeId=598019490e713, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Apr 24 22:45:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219469, encodeId=011d219469d3, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:31:53 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219370, encodeId=c03b2193e0c1, content=支持一下,需要大家努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Jul 07 07:01:34 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219243, encodeId=abcd2192439a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Jul 06 20:07:03 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219219, encodeId=77ee21921960, content=确实应该严格限制抗生素的应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Thu Jul 06 18:49:33 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219214, encodeId=6fe8219214a2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:04:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219203, encodeId=4f2e2192032a, content=严格用药指征,严格限制抗生素使用,。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jul 06 16:02:09 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 dhzzm

    学习了分享了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1949077, encodeId=598019490e713, content=<a href='/topic/show?id=72459589567' target=_blank style='color:#2F92EE;'>#重点监控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95895, encryptionId=72459589567, topicName=重点监控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Apr 24 22:45:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219469, encodeId=011d219469d3, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:31:53 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219370, encodeId=c03b2193e0c1, content=支持一下,需要大家努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Jul 07 07:01:34 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219243, encodeId=abcd2192439a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Jul 06 20:07:03 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219219, encodeId=77ee21921960, content=确实应该严格限制抗生素的应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Thu Jul 06 18:49:33 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219214, encodeId=6fe8219214a2, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jul 06 18:04:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219203, encodeId=4f2e2192032a, content=严格用药指征,严格限制抗生素使用,。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jul 06 16:02:09 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 1e0f8808m18(暂无匿称)

    严格用药指征,严格限制抗生素使用,。

    0

相关资讯

Plos one:抗菌药物降阶梯治疗的好处和意想不到的后果

连续抗菌药物降级治疗旨在当实验室检验确定药物敏感性时转换为敏感药物,以此达到最大限度地降低对高广谱经验抗微生物药物的耐药性。虽然临床广泛使用,但是抗菌药物的降级仍然难以理解。各种干预和结果的定义在不同的研究之间各不相同。近期,一项发表在Plos one杂志上的研究使用铜绿假单胞菌在重症监护室中的传播和进化模型,以评估药物降级对患者结局的影响。在此项研究中,抗菌药物降级减少了高广谱药物的使用,并能保

J Antimicrob Chemother:围手术期抗菌药物预防 医生们这样做……

2016年12月,发表在《J Antimicrob Chemother》的一项由南非科学家进行的研究介绍了34家南非医院中药师驱动的前瞻性审计和反馈改进模型,以进行围手术期抗菌药物预防。

Fertil Steril:胚泡移植前糖皮质激素和抗菌药物使用对妊娠率有何影响?

2017年6月,发表在《Fertil Steril》的一项由美国科学家进行的回顾性队列研究,考察了胚泡移植(ET)前糖皮质激素和抗菌药物使用的结局。

Lancet Infect Dis:术前抗菌药物预防 手术前早期还是晚期给药?

术前早期还是晚期使用抗菌药物预防?2017年6月,发表在《Lancet Infect Dis》的一项3期随机对照研究调查了术前抗菌药物预防最佳给药时机。

常用抗菌药物相互作用表,果断收藏!

1、β-内酰胺类抗菌药物2、氨基糖苷类抗菌药物3、氯霉素4、大环内酯类5、四环素类6、多粘菌素类7、抗结核药8、(去甲)万古霉素9、甲硝唑10、呋喃类11、喹诺酮类12、磺胺药13、抗真菌药

Crit Care Med:脓毒症患者第二剂抗菌药物延迟 后果很严重

2017年6月,发表在《Crit Care Med》的一项由美国科学家进行的研究从急诊入院的脓毒症患者第二剂抗菌药物延迟:发生率、危险因素及结局

Baidu
map
Baidu
map
Baidu
map